Login
Companies $OVID
$2.44 +$0.04 (1.6%) After hours
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

ovidrx.com

What Do They Do?

Develops small-molecule medicines for epilepsies, psychoses and schizophrenia for people with neurological and psychiatric conditions.

How Do They Make Money?

License partners pay for drug rights through fees and royalties; Ovid has also received one-time upfront payments, and license fees are tied to the license start and delivery of licensed material.

FY2025 revenue

Who Are Their Customers?

Takeda and Ligand are counterparties to Ovid's royalty and licensing arrangements; Ovid may work with third parties to commercialize candidates in markets where doing so is less capital efficient.

Do Revenues Turn Into Profits?

No. It lost $17.4M in FY2025.

Operating income, FY2025
−585% of revenue
▲ +31% (Loss) vs FY2024 (−$61.9M, −10934%)
Net income, FY2025
−240% of revenue
▲ +34% (Loss) vs FY2024 (−$26.4M, −4670%)
Free cash flow, FY2025
−529% of revenue
▲ +32% (Loss) vs FY2024 (−$56M, −9899%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $132K in Q3 FY2025
Net income
▼ −71% (Loss)
vs −$12.2M in Q3 FY2025
  • Jul 5, 2026 CFO Jeffrey Rona left and Charles Carter was appointed CFO Carter succeeded Rona as chief financial officer and took on the principal financial, accounting and secretary roles.

Shrinking. Revenue fell 97% in 4 years, from $208.4M in FY2021 to $7.3M in FY2025, about 57% a year.

Broader treatment targets The older report centers on rare epilepsies and seizure-related neurological disorders; the latest report also targets psychosis associated with Parkinson's disease and Lewy body dementia, schizophrenia and mood disorders.

Pipeline modalities The older report includes genetic therapies, including antisense oligonucleotides, in the pipeline; the latest report describes the pipeline as consisting of small-molecule programs.

Who Do They Compete With?

Competes with UCB, Jazz Pharmaceuticals, SK Biopharmaceuticals, Harmony Biosciences, Xenon Pharmaceuticals, Acadia Pharmaceuticals, and Axonis Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support